Luminex Stock Price, News & Analysis (NASDAQ:LMNX)

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex declared a quarterly dividend on Wednesday, July 31st. Investors of record on Thursday, September 26th will be paid a dividend of $0.09 per share on Thursday, October 17th. This represents a $0.36 dividend on an annualized basis and a yield of 1.80%. The ex-dividend date is Wednesday, September 25th. This is a boost from Luminex's previous quarterly dividend of $0.06. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) posted its quarterly earnings results on Wednesday, July, 31st. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.09. The medical instruments supplier had revenue of $83.06 million for the quarter, compared to analyst estimates of $81.61 million. Luminex had a negative return on equity of 0.78% and a negative net margin of 0.80%. The business's revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.15 EPS. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Luminex.

Luminex updated its third quarter 2019 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of for the period. The company issued revenue guidance of $80-83 million, compared to the consensus revenue estimate of $83.01 million.

3 brokerages have issued 12 month price targets for Luminex's stock. Their predictions range from $21.00 to $33.00. On average, they anticipate Luminex's share price to reach $27.00 in the next year. This suggests a possible upside of 34.7% from the stock's current price. View Analyst Price Targets for Luminex.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

Media stories about LMNX stock have trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Luminex earned a news impact score of -3.8 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Luminex.

Luminex saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 1,000,000 shares, a drop of 30.6% from the August 30th total of 1,440,000 shares. Based on an average daily trading volume, of 189,400 shares, the days-to-cover ratio is presently 5.3 days. Currently, 2.4% of the company's stock are sold short. View Luminex's Current Options Chain.

Some companies that are related to Luminex include Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Cantel Medical (CMD), Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Inspire Medical Systems (INSP), AtriCure (ATRC), Orthofix Medical (OFIX), Silk Road Medical (SILK) and Cryolife (CRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), Mondi (MNDI), Alphabet (GOOG), Intel (INTC), Micron Technology (MU), Nektar Therapeutics (NKTR), Rocket Pharmaceuticals (RCKT), Verizon Communications (VZ), Cree (CREE) and Ligand Pharmaceuticals (LGND).

Luminex's stock is owned by many different of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.07%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Nachum Shamir and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $20.04.

Luminex has a market capitalization of $902.80 million and generates $315.82 million in revenue each year. The medical instruments supplier earns $18.51 million in net income (profit) each year or $0.48 on an earnings per share basis. Luminex employs 988 workers across the globe.View Additional Information About Luminex.

The official website for Luminex is http://www.luminexcorp.com/.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]